Ray Therapeutics Inc (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting (and will not require light-enhancing goggles). Our studies have shown for the first time that our proprietary ChRown optogenetic protein can restore high levels of visual acuity, contrast sensitivity and visual field. RayTx lead asset, RTx-015, is expected to address the huge unmet medical in people suffering from many forms of retinal blindness (independent of the underlying genetic cause), including those with advanced age-related macular degeneration. RayTx has partnered with a world-leading AAV gene therapy manufacturer is utilizing their proprietary commercial manufacturing process and analytics to maximally de-risk clinical development. RayTx anticipates clinical trials will begin by the end of 2023 in our initial indication, retinitis pigmentosa.
View Top Employees from Ray Therapeutics, Inc.Website | http://www.raytherapeutics.com |
Employees | 18 (11 on RocketReach) |
Founded | 2021 |
Address | 1 Sansome St 3500, San Francisco, California 94104, US |
Industry | Biotechnology Research |
Looking for a particular Ray Therapeutics, Inc. employee's phone or email?
Terry O'Neal is the COO of Ray Therapeutics, Inc..
11 people are employed at Ray Therapeutics, Inc..
Ray Therapeutics, Inc. is based in San Francisco, California.